If you have these signs of arrhythmia, “this treatment must be permanently stopped”

earthpressnews
If you have these signs of arrhythmia this treatment must

The Medicines Agency warns of an increased risk of atrial fibrillation in patients taking anti-triglyceride treatments.

The Medicines Agency (ANSM) reports a “increased” risk of atrial or atrial fibrillation in patients suffering from cardiovascular diseases or presenting cardiovascular risk factors, and treated with ethyl esters of Omega-3 acids. When we talk about “atrial fibrillation” it is to designate thecardiac arrhythmia due to atrial fibrillation. This is a heart rhythm disorder which results in a succession of rapid, disordered heart contractions at the level of the atria of the heart. Concretely, the heartbeats are irregular and often fast. “It is a common heart disease and which can go unnoticed for a long time but whose The most serious consequences are the occurrence of a stroke. which can leave lifelong consequences.Dr Marc Druet, general practitioner, told us in a previous interview.

Dizziness, palpitations should alert

The medications targeted here are prescribed to lower triglyceride levels in the blood when diet and other non-drug measures have not been sufficient. They are in the form of 1g capsules of fatty acidsprescribed for adults and marketed under the names Lipidem®, Ysomega®, Omacor®, Mednutriflex Omega®… Warning: this is not just a warning. According to the ANSM, treatment must “to be permanently arrested” en case of occurrence of atrial fibrillation. The warning symptoms are:

  • A feeling of dizziness
  • A asthenia (great fatigue even after rest)
  • Of the palpitations Or a feeling of tightness in the chest
  • A shortness of breath

A higher risk beyond 4 grams per day

General practitioners, cardiologists, geriatricians, endocrinologists, specialists in internal medicine, community and hospital pharmacists must advise their patients to consult a doctor in the event of symptoms suggestive of atrial fibrillation. The risk of atrial fibrillation is higher with a dose of 4g/day. The European Medicines Agency (EMA) has recommended an update of the SmPC and the package leaflet for medicines based on ethyl esters of Omega-3 acids to take into account the risk of atrial fibrillation. The EMA also recommended including atrial fibrillation among the “common” side effects.


jdf4